Natera Ltd.: Enhanced Market Penetration in Women’s Health

Natera, Inc. demonstrated remarkable growth in its Q2 2024 earnings, underpinned by diversified advancements across its portfolio, including women’s health, organ health, and oncology segments. Revenue increased significantly, achieving a 58% rise compared to Q2 of the previous year, with a total nearing $1.5 billion forecasted for the full year. The quarterly performance highlighted volume growth primarily driven by a 23% increase in the year-over-year comparison and also marked by quarter-overquarter improvement in average selling price (ASP).